Pharmapedia Pro
Medicines/Generics/Human Insulin

Human Insulin

Generic medicine reference

Not yet clinically reviewed

This entry was migrated from the earlier Pharmapedia app bundle and has not been reviewed by a named clinician on this site. It is provided for educational reference only — verify dosage and safety information against current, authoritative sources and a qualified healthcare professional before any clinical use.

Spot an error in this entry? Submit a correction
Overview
Insulin glargine is a long-acting insulin used to treat type 1 and type 2 diabetes in certain patients to improve and maintain blood glucose levels. Insulin glargine is a man-made form of human insulin that is used once daily to provide a base level of insulin that keeps working for 24 hours or longer. Insulin glargine is available under the brand names Lantus , Basaglar , Toujeo, Semglee , and Rezvoglar . Rezvoglar, Lantus, Semglee, and Toujeo are FDA-approved to be used for use in adult and pediatric patients with type 1 and type 2 diabetes. Basasglar is FDA-approved to be used by adults for type 2 diabetes and also for adults and pediatric patients with type 1 diabetes . In patients with type 1 diabetes, insulin glargine must be used together with a short-acting insulin.
Indications
Insulin glargine is a long-acting insulin used to treat type 1 and type 2 diabetes in certain patients to improve and maintain blood glucose levels. Insulin glargine is a man-made form of human insulin that is used once daily to provide a base level of insulin that keeps working for 24 hours or longer. Insulin glargine is available under the brand names Lantus , Basaglar , Toujeo, Semglee , and Rezvoglar . Rezvoglar, Lantus, Semglee, and Toujeo are FDA-approved to be used for use in adult and pediatric patients with type 1 and type 2 diabetes. Basasglar is FDA-approved to be used by adults for type 2 diabetes and also for adults and pediatric patients with type 1 diabetes . In patients with type 1 diabetes, insulin glargine must be used together with a short-acting insulin.
Contraindications
You should not use insulin glargine if you are allergic to insulin, or if you are having an episode of hypoglycemia (low blood sugar) or diabetic ketoacidosis (call your doctor for treatment). Different brands of insulin glargine are specifically approved for different age groups and different diabetes types. The safety and effectiveness of insulin glargine in pediatric patients younger than 6 years of age with type 1 diabetes and pediatric patients with type 2 diabetes has not been established. Tell your doctor if you have ever had: liver or kidney disease; or heart failure or other heart problems. Tell your doctor if you also take pioglitazone or rosiglitazone (sometimes contained in combinations with glimepiride or metformin). Taking certain oral diabetes medicines while you are using insulin may increase your risk of serious heart problems.
Side Effects
Common insulin glargine side effects may include low blood sugar , swelling, weight gain, allergic reaction, itching, rash, or thickening or hollowing of the skin where you injected the medicine (lipodystrophy). Serious insulin glargine side effects Get emergency medical help if you have signs of insulin allergy: redness or swelling where an injection was given, itchy skin rash over the entire body, trouble breathing, fast heartbeats, feeling like you might pass out, or swelling in your tongue or throat. Insulin glargine may cause other serious side effects. Call your doctor at once if you have: rapid weight gain, swelling in your feet or ankles; shortness of breath ; or low blood potassium--leg cramps, constipation , irregular heartbeats, fluttering in your chest, increased thirst or urination, numbness or tingling, muscle weakness or limp feeling. This is not a complete list of side effects, and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Warnings
Never share an injection pen, even if you changed the needle.
High Risk Groups
Never share an injection pen, even if you changed the needle.
Adult Dosage
0.05 to 0.2 IU/ kg (0.12 (0.125)) 12 hourly IV — Dose depends upon blood sugar level 35 to 70 IU (52 (52.5)) As recommended. SC — In divided doses. Dose depends upon blood sugar level
Child Dosage
0.25 to 0.5 IU/kg (0.38 (0.375)) 24 hourly Subcutaneous — -
Neonatal Dosage
0.25 to 0.5 IU/kg (0.38 (0.375)) 24 hourly Subcutaneous —
Drug Interactions
Many drugs can affect your blood sugar and may also affect insulin glargine. This includes prescription and over-the-counter medicines, vitamins, and herbal products . Tell your doctor about all other medicines you use. Not all possible interactions are listed here. Tell your doctor if you also take pioglitazone or rosiglitazone (sometimes contained in combinations with glimepiride or metformin). Taking certain oral diabetes medicines while you are using insulin may increase your risk of serious heart problems.
Storage
Inj Store at room temperature, Below 15°C or in refrigerator. Do not Freeze. Protect from Sunlight. Use within 2 years(at 4C) if refrigerated and within 1 month if kept at room temperature.

Available Brands in Pakistan

19 active brands listed alphabetically.

ACTRAPID®

Active

Novo Nordisk Pharma (Pvt.) Ltd. DSL: 636

DML: ACTRAPID®

Inj

ACTRAPID HM

Active

NOVO NORDISK SCIENTIFIC OFFICE

DML: ACTRAPID HM

Inj

ACTRAPID ® INNOLET ®

Active

NOVO NORDISK SCIENTIFIC OFFICE

DML: ACTRAPID ® INNOLET ®

Inj

ACTRAPID NOVOLET

Active

NOVO NORDISK SCIENTIFIC OFFICE

DML: ACTRAPID NOVOLET

Inj

ACTRAPID PENFILL

Active

NOVO NORDISK SCIENTIFIC OFFICE

DML: ACTRAPID PENFILL

Inj

HUMULIN-ULTRA LENTE

Active

ELI LILLY PAKISTAN (PVT) LTD.

DML: HUMULIN-ULTRA LENTE

Inj

INSUGET R

Active

GETZ PHARMA PAKISTAN (PVT) LTD.

DML: INSUGET R

Inj

INSULATARD®

Active

Novo Nordisk Pharma (Pvt.) Ltd. DSL: 636

DML: INSULATARD®

Inj

INSULATARD ® INNOLET ®

Active

NOVO NORDISK SCIENTIFIC OFFICE

DML: INSULATARD ® INNOLET ®

Inj

INSUMAN RAPID

Active

SANOFI AVENTIS (PAKISTAN) LTD.

DML: INSUMAN RAPID

Inj

JUSLINE REGULAR

Active

JULPHAR PAKISTAN

DML: JUSLINE REGULAR

Inj

MIXTARD®

Active

Novo Nordisk Pharma (Pvt.) Ltd. DSL: 636

DML: MIXTARD®

Inj

MIXTARD 30 INNOLET

Active

NOVO NORDISK SCIENTIFIC OFFICE

DML: MIXTARD 30 INNOLET

Inj

MIXTARD 30 NOVOLET

Active

NOVO NORDISK SCIENTIFIC OFFICE

DML: MIXTARD 30 NOVOLET

Inj

NOVOPEN 3

Active

NOVO NORDISK SCIENTIFIC OFFICE

DML: NOVOPEN 3

Inj

SAMULIN

Active

SAMI PHARMACEUTICALS (PVT) LTD.

DML: SAMULIN

Inj

ZANSULIN

Active

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD.

DML: ZANSULIN

Inj

ZANSULIN70/30

Active

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD.

DML: ZANSULIN70/30

Susp

ZANSULIN REGULAR

Active

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD.

DML: ZANSULIN REGULAR

Inj

1 additional record is present but flagged "Unverified / Legacy" and not listed.